Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was downgraded by investment analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research report issued on Wednesday.

A number of other research firms have also weighed in on ALNY. Cowen and Company reissued a “buy” rating and set a $100.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday, July 11th. Vetr lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $71.50 target price on the stock. in a report on Monday, May 15th. Piper Jaffray Companies set a $118.00 target price on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, May 15th. Barclays PLC boosted their target price on shares of Alnylam Pharmaceuticals from $50.00 to $70.00 and gave the stock an “equal weight” rating in a report on Thursday, August 10th. Finally, Credit Suisse Group boosted their target price on shares of Alnylam Pharmaceuticals from $90.00 to $96.00 and gave the stock an “outperform” rating in a report on Tuesday, June 27th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $81.74.

Shares of Alnylam Pharmaceuticals (NASDAQ ALNY) traded up 1.22% during trading on Wednesday, reaching $81.35. 587,004 shares of the company traded hands. The company has a 50 day moving average price of $80.75 and a 200 day moving average price of $63.02. Alnylam Pharmaceuticals has a 12-month low of $31.38 and a 12-month high of $86.92. The firm’s market capitalization is $7.46 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.22) by $0.12. Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The business had revenue of $15.93 million for the quarter, compared to the consensus estimate of $23.86 million. During the same period in the previous year, the firm earned ($1.05) earnings per share. The company’s revenue was up 82.9% compared to the same quarter last year. On average, equities analysts predict that Alnylam Pharmaceuticals will post ($5.21) EPS for the current year.

TRADEMARK VIOLATION WARNING: “BidaskClub Downgrades Alnylam Pharmaceuticals, Inc. (ALNY) to Buy” was reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/08/16/bidaskclub-downgrades-alnylam-pharmaceuticals-inc-alny-to-buy.html.

In related news, major shareholder Sanofi bought 297,501 shares of the company’s stock in a transaction that occurred on Wednesday, May 31st. The shares were bought at an average price of $71.87 per share, for a total transaction of $21,381,396.87. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Akshay Vaishnaw sold 11,000 shares of the business’s stock in a transaction on Tuesday, May 23rd. The shares were sold at an average price of $75.00, for a total transaction of $825,000.00. Following the transaction, the executive vice president now owns 21,297 shares in the company, valued at approximately $1,597,275. The disclosure for this sale can be found here. 4.30% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. First Manhattan Co. bought a new position in Alnylam Pharmaceuticals during the first quarter worth about $135,000. QS Investors LLC increased its position in Alnylam Pharmaceuticals by 59.7% in the second quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock valued at $192,000 after buying an additional 900 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in Alnylam Pharmaceuticals by 7.0% in the second quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 167 shares during the last quarter. CIBC Asset Management Inc acquired a new position in Alnylam Pharmaceuticals during the second quarter valued at $221,000. Finally, Neuberger Berman Group LLC acquired a new position in Alnylam Pharmaceuticals during the second quarter valued at $229,000. Institutional investors own 88.99% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.